Novo Nordisk has advised the Therapeutics Goods Administration (TGA) that supply of Ozempic^® (semaglutide), a medicine approved for use in adults with type 2 diabetes, will continue to be limited until 31 December 2025 in Australia. This is due to the continued, unprecedented demand for Ozempic^® (semaglutide) in Australia and around the world.

Novo Nordisk has continued to make significant investments to expand its global manufacturing capacity and meet demand to the greatest extent possible. Since 2023, Novo Nordisk has committed to investing at least 27 billion USD (41 billion AUD) to build production capacity. However, it takes time to build supply levels to meet global and local demand.

It’s important to continue to follow the joint guidance issued by the TGA and various professional bodies on this matter, and additional information about Ozempic^® (semaglutide) supply on the TGA website.

Novo Nordisk will continue to work with the TGA to provide updates on this matter. 

Novo Nordisk has advised the TGA about the planned phase out of Novo Nordisk insulin products, which will occur over the next two years and will focus on older generation products with multiple presentations. This is part of a global insulin portfolio consolidation strategy and is not a result of any safety, efficacy or quality-related concerns.

The table below lists the products and presentations that will be impacted in Australia.

We remain committed to working closely with health authorities, the medical community, and patient advocacy groups, in accordance with local regulations, to ensure that patients have access to the medications they need.

We will provide support materials to healthcare professionals to assist patients transitioning to alternative treatments closer to the timings of each product phase out.